2C-B

Uses your system voice; voice and rate in settings.

Snapshot

≈ 6 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families. The drug is used as a recreational drug and is usually taken orally. 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects. Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin. The drug acts as a potent partial agonist of the serotonin 5-HT 2 receptors, including of the serotonin 5-HT 2A receptor. It produces psychedelic-like effects in animals. Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others. 2C-B was developed by Alexander Shulgin in 1974 and was described by him in the scientific literature in 1975. The drug emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s. Subsequently, it became a controlled substance in the United States in the mid-1990s. 2C-B was one of the first 2C psychedelics to be described. It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs.

2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families. The drug is used as a recreational drug and is usually taken orally. 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects. Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin. The drug acts as a potent partial agonist of the serotonin 5-HT 2 receptors, including of the serotonin 5-HT 2A receptor. It produces psychedelic-like effects in animals. Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others. 2C-B was developed by Alexander Shulgin in 1974 and was described by him in the scientific literature in 1975. The drug emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s. Subsequently, it became a controlled substance in the United States in the mid-1990s. 2C-B was one of the first 2C psychedelics to be described. It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs. 2C-B acts as a potent partial agonist of the serotonin 5-HT 2 receptors, including of the serotonin 5-HT 2A and 5-HT 2C receptors and to a lesser extent of the serotonin 5-HT 2B receptor. In one study, it had ( ) values of 1.2 nM (101%) at the serotonin 5-HT 2A receptor, 13 nM (97%) at the serotonin 5-HT 2B receptor, and 0.63 nM (98%) at the serotonin 5-HT 2C receptor. In earlier studies, 2C-B was found to be a low-efficacy serotonin 5-HT 2A and 5-HT 2C receptor partial agonist or even antagonist. However, subsequent studies have consistently found higher efficacy of 2C-B at these receptors. In addition to the serotonin 5-HT 2 receptors, 2C-B also shows lower affinity for other serotonin receptors, such as the serotonin 5-HT 1A and 5-HT 1B receptors among others. However, while 2C-B itself was not assessed, other 2C derivatives showed little activity as serotonin 5-HT 1A receptor agonists ( = >3,000 nM). At the serotonin 5-HT 2A receptor, 2C-B has subsequently been identified as a biased agonist, acting as a near-full agonist of receptor in terms of Ca 2+ mobilization ( = 1.64 nM; = 92.6%) but with 6-fold lower potency as a moderate-efficacy partial agonist in terms of β-arrestin2 recruitment ( = 10.0 nM; = 60.1%). However, serotonin itself showed about 42-fold greater potency in activating Ca 2+ mobilization than β-arrestin2 signaling in the study. The implications of the preceding findings are not fully clear. 2C-B has been reported to be an allosteric or non-competitive serotonin transporter (SERT) inhibitor or serotonin reuptake inhibitor, albeit of very low potency. Although 2C-B itself was not evaluated, other closely related members of the 2C series, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2, all showed no activity as monoamine releasing agents of serotonin, norepinephrine, or dopamine ( = >100,000 nM or "inactive"). 2C-B shows dopaminergic actions mediated by the dopamine transporter (DAT) in monkeys but not in rodents. 2C-B produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It shows reinforcing effects in monkeys but not in rodents. The drug also shows potent and efficacious anti-inflammatory effects in preclinical research. In contrast to MDMA, which robustly increases oxytocin levels and produces associated entactogenic effects, 2C-B minimally affects oxytocin levels in humans. 2C-B - The Shulgin Index The Big & Dandy 2C-B Thread - Bluelight Molecular Memoirs: 2C-B, The "Warm Hug" - The Shulgin Foundation 2C-B, the Forgotten Psychedelic: Understanding the "Love Child" of Alexander and Ann Shulgin - Psychedelics.com Forgotten Psychedelics: What Is 2C-B? - Psychedelic Spotlight Is 2C-B a Psychedelic Drug? - Psychedelic Science Review (PSR) 2C-B: Effects, Dosage, & Safety - Tripsitter 2C-B - TripSit 2C-B – Graceful, Erotic, and Sensual? - HealingMaps 2C-B: If LSD and MDMA had a baby - PsychedelicHealth 2C-B Is the Drug Taking Over the UK's Clubs - Vice

Text derived from https://en.wikipedia.org/w/index.php?oldid=1375574978 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

Extracted from the cited revision's reference blocks; absent citations are not invented.